Form 4: Nuvalent CEO Executes Stock Option Plan

Nuvalent CEO James Richard Porter exercised options and sold 30,000 shares of Class A Common Stock under a 10b5-1 plan.

Summary

• CEO James Richard Porter exercised 30,000 stock options at a strike price of $18.93.
• Following the exercise, the CEO sold the 30,000 shares in multiple transactions at weighted average prices ranging from $87.97 to $89.63.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2025.
• The CEO's direct beneficial ownership of Class A Common Stock stands at 324,879 shares following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive financial management.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.
• The exercise of options demonstrates the CEO's continued long-term alignment with the company's equity performance.

Negatives

• The CEO reduced his direct holdings of Class A Common Stock by 30,000 shares through the sale.

Risks

• Future sales by insiders under 10b5-1 plans may occur, which could influence market perception of the stock price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for executives in the biotechnology sector to manage personal liquidity and diversify holdings, and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice for C-suite executives at publicly traded biotech firms like Nuvalent to avoid potential conflicts regarding material non-public information.
• The scale of the sale relative to the CEO's total holdings is consistent with typical executive compensation and liquidity management patterns.

Stakeholder Impact

• Shareholders should note that the CEO remains a significant stakeholder with 324,879 shares.

Next Steps

• Continued monitoring of future Form 4 filings for additional transactions under the established 10b5-1 plan.

Key Dates

Keywords

Nuvalent, NUVL, Insider Trading, Form 4, Biotech, Executive Compensation